A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0 (PRECISE)
A Prospective, Randomized, Controlled Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0
Sponsor: Medtronic Surgical Technologies
Terminated
Termination due to acquisition of PEAK Surgical by Medtronic
Other terminated trials from Medtronic Surgical Technologies
Listed as NCT01284491, this NA trial focuses on Macromastia and remains terminated or withdrawn. Sponsored by Medtronic Surgical Technologies, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Surgical Technologies
For direct contact, visit the study record on ClinicalTrials.gov .